Genitourinary Cancer Clinical Trials

A listing of Genitourinary Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 183 clinical trials
Safety and Efficacy Study of AVB-S6-500 in Patients With Advanced Clear Cell Renal Cell Carcinoma

This is a Phase 1b/2 study of AVB-S6-500 designed to evaluate the safety and efficacy of AVB-S6-500 in combination with cabozantinib in subjects with advanced clear cell renal cell carcinoma (ccRCC) that have progressed on or after at least one prior line of treatment. The phase 1b portion of the …

major surgery
measurable disease
cabozantinib
carcinoma
clear cell renal cell carcinoma
  • 0 views
  • 16 Sep, 2021
  • 10 locations
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902) or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib Versus Pembrolizumab and Lenvatinib for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)

The goal of this study is to evaluate the efficacy and safety of pembrolizumab plus belzutifan plus lenvatinib or pembrolizumab/quavonlimab plus lenvatinib versus pembrolizumab plus lenvatinib as first-line treatment in participants with advanced clear cell renal cell carcinoma (ccRCC). The primary hypotheses are (1) pembrolizumab plus belzutifan plus lenvatinib is …

pembrolizumab
systemic therapy
carcinoma
clear cell renal cell carcinoma
lenvatinib
  • 3 views
  • 26 Sep, 2021
  • 93 locations
Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61)

This study is being performed as a single-arm open-label study in order to rapidly provide information on the potential benefits of the combination of pembrolizumab and lenvatinib in participants with previously untreated advanced/metastatic non-clear cell renal cell carcinoma.

measurable disease
karnofsky performance status
systemic therapy
pembrolizumab
carcinoma
  • 0 views
  • 26 Sep, 2021
  • 56 locations
Trilaciclib a CDK 4/6 Inhibitor in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab

This is a Phase 2, multicenter, randomized, open-label study evaluating the safety and efficacy of trilaciclib administered with platinum-based chemotherapy followed by trilaciclib administered with avelumab maintenance therapy compared with platinum-based chemotherapy followed by avelumab maintenance therapy in patients receiving first-line treatment for advanced/metastatic bladder cancer.

avelumab
gemcitabine
metastatic bladder cancer
bladder tumor
bladder cancer
  • 0 views
  • 26 Sep, 2021
  • 7 locations
A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)

This study will compare the efficacy and safety of two doses of belzutifan in participants with advanced renal cell carcinoma (RCC) with clear cell component after prior therapy. The primary hypothesis is that the higher dose of belzutifan is superior to the standard dose in terms of objective response rate …

growth factor
measurable disease
karnofsky performance status
carcinoma
tyrosine
  • 1 views
  • 26 Sep, 2021
  • 47 locations
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer The PDIGREE Study

This phase III trial compares the usual treatment (treatment with ipilimumab and nivolumab followed by nivolumab alone) to treatment with ipilimumab and nivolumab, followed by nivolumab with cabozantinib in patients with untreated renal cell carcinoma that has spread to other parts of the body. The addition of cabozantinib to the …

monoclonal antibodies
tremelimumab
measurable disease
nephrectomy
nivolumab
  • 157 views
  • 27 Sep, 2021
  • 689 locations
A Phase II Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma

This is a Phase II, multicenter, open-label, single arm, 2-stage study of tazemetostat 800 mg BID (twice daily) and 1600 mg QD (once daily). Subjects will be screened for eligibility within 21 days of the planned date of the first dose of tazemetostat and enrolled into one of 8 cohorts: …

kidney function tests
beta human chorionic gonadotropin
monoclonal antibodies
measurable disease
epithelioid sarcoma
  • 2 views
  • 27 Sep, 2021
  • 25 locations
A Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors

This clinical trial will evaluate DS-6000a in participants with advanced renal cell carcinoma (RCC) and ovarian cancer (OVC). The main goals of this study will be to investigate the recommended dose of DS-6000a that can be given safely to participants, assess the side effects of DS-6000a, and evaluate the effectiveness …

advanced renal cell carcinoma
carcinoma
cancer
cancer of the ovary
  • 0 views
  • 24 Sep, 2021
  • 5 locations
Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab

In this study, the Phase Ib portion aims to establish safety and tolerability of ARRY-614 with either nivolumab or ipilimumab and to determine a recommended phase II dose of ARRY-614 in combination with either nivolumab or nivolumab+ipilimumab immunotherapy in patients with selected advanced solid tumors. The Phase II portion will …

neutrophil count
serum bilirubin
tubal ligation
measurable disease
nivolumab
  • 10 views
  • 26 Sep, 2021
  • 1 location
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors Non-Hodgkin Lymphoma or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)

This phase II Pediatric MATCH trial studies how well ensartinib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with ALK or ROS1 genomic alterations that have come back (recurrent) or do not respond to treatment (refractory) and have spread to other places in the body (advanced). …

platelet transfusion
cancer therapy
cellular therapy
measurable disease
solid tumor
  • 68 views
  • 26 Sep, 2021
  • 78 locations